Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × cabozantinib × NET × Clear all

Phase

Status

Recruiting 3 Active not recruiting 3 Unknown 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 2 Endocrine 2 Tumor-Agnostic 1 Thoracic 1 NET 1 Head & Neck 1 Gastrointestinal 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 4 Temozolomide 3 lanreotide 2 Everolimus 2 Biopsy 2 177Lu-octreotide, DOTA(0)-Tyr(3)- 2 (177)Lu-DOTA-EB-TATE 2 surufatinib 1 sintilimab 1 regorafenib 1 recombinant interferon alpha 2b-like protein 1 pembrolizumab 1 olaparib 1 gallium Ga 68 dotatate 1 copper dotatate CU-64 1 cabozantinib 1 anlotinib 1 Yttrium-90 1 Tomography, Emission-Computed, Single-Photon 1 Thalidomide 1 Tegafur 1 Surgical Procedures, Operative 1 Somatostatin 1 Rose Bengal B 1 Positron Emission Tomography Computed Tomography 1 Plastic Surgery Procedures 1 Phlebotomy 1 Nivolumab 1 Needles 1 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04427787 2021-09-05

LOLA

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Unknown

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡